Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Cash (2016 - 2025)

Historic Change in Cash for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$1.8 million.

  • Lineage Cell Therapeutics' Change in Cash rose 354.08% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 44301.57%. This contributed to the annual value of $10.4 million for FY2024, which is 5692.55% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Change in Cash stood at -$1.8 million for Q3 2025, which was up 354.08% from -$5.6 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Change in Cash's 5-year high stood at $23.5 million during Q1 2021, with a 5-year trough of -$46.1 million in Q3 2022.
  • For the 5-year period, Lineage Cell Therapeutics' Change in Cash averaged around $410210.5, with its median value being -$1.2 million (2021).
  • Over the last 5 years, Lineage Cell Therapeutics' Change in Cash had its largest YoY gain of 793174.06% in 2021, and its largest YoY loss of 1062291.67% in 2021.
  • Lineage Cell Therapeutics' Change in Cash (Quarter) stood at -$5.1 million in 2021, then plummeted by 164.52% to -$13.4 million in 2022, then surged by 129.88% to $4.0 million in 2023, then surged by 352.1% to $18.0 million in 2024, then plummeted by 109.96% to -$1.8 million in 2025.
  • Its Change in Cash stands at -$1.8 million for Q3 2025, versus -$5.6 million for Q2 2025 and $2.0 million for Q1 2025.